NIT
MACK

NumerixS Investment Technologies’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

NumerixS Investment Technologies’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,408
Closed -$83K – 1476
2017
Q1 		$83K Buy
3,408
+3,306
+3,241% +$82.7K 0.01% 934
2016
Q4 		$3K Buy
+102
New +$4.35K ﹤0.01% 1081
2016
Q3 		– Sell
-1,767
Closed -$75K – 1425
2016
Q2 		$75K Buy
+1,767
New +$96.3K 0.01% 913

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

NumerixS Investment Technologies's MACK Position: Q2 2017 in Review

NumerixS Investment Technologies sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 3,408 shares — an estimated $83K sold.

NumerixS Investment Technologies first reported a position in MACK in Q2 2016 and held it in 3 quarters. The position peaked at $83K in Q1 2017. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

  • NumerixS Investment Technologies reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • NumerixS Investment Technologies sold 3,408 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $83K.
  • NumerixS Investment Technologies first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2016 and held it in 3 quarters.
  • NumerixS Investment Technologies's Merrimack Pharmaceuticals, Inc. position peaked at $83K in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on NumerixS Investment Technologies's 13F filing for Q2 2017, filed 9 Aug 2017.